黃展鵬
黃展鵬
職稱:研究員
科室:轉(zhuǎn)化醫(yī)學(xué)研究中心
學(xué)位/學(xué)歷:博士
導(dǎo)師資格:博士生導(dǎo)師
職務(wù):輔助循環(huán)實(shí)驗(yàn)室副主任
簡(jiǎn)介:長(zhǎng)期從事心血管發(fā)育與疾病的分子機(jī)制研究,,主要從分子、細(xì)胞,、小鼠模型以及病人多個(gè)層面研究蛋白質(zhì)基因網(wǎng)絡(luò)和非編碼RNA基因網(wǎng)絡(luò)如何協(xié)同調(diào)控心血管疾病的發(fā)生發(fā)展,,并探索新的心血管疾病基因療法。
出診時(shí)間
專家門診
周一
Mon
周二
Tue
周三
Wed
周四
Thur
周五
Fri
周六
Sat
周日
Sun
上午
AM
下午
PM
出診時(shí)間以實(shí)際為準(zhǔn)

醫(yī)療特長(zhǎng):

    長(zhǎng)期從事心血管發(fā)育與疾病的分子機(jī)制研究,,主要從分子,、細(xì)胞、小鼠模型以及病人多個(gè)層面研究蛋白質(zhì)基因網(wǎng)絡(luò)和非編碼RNA基因網(wǎng)絡(luò)如何協(xié)同調(diào)控心血管疾病的發(fā)生發(fā)展,,并探索新的心血管疾病基因療法,。

研究方向:

    心血管疾病的基因調(diào)控網(wǎng)絡(luò)

主要教育和工作經(jīng)歷:

    2018.12 至今,  國家衛(wèi)健委輔助循環(huán)重點(diǎn)實(shí)驗(yàn)室,,副主任

    2017.11 至今,,  中山大學(xué)附屬第一醫(yī)院,研究員,,博士生導(dǎo)師

    2010.11-2017.11,,美國哈佛醫(yī)學(xué)院波士頓兒童醫(yī)院,講師

    2009.8-2010.10,, 美國哈佛醫(yī)學(xué)院波士頓兒童醫(yī)院,,博士后

    2008.2-2009.7,  美國北卡萊羅納州大學(xué)教皇山分校,,博士后

    2002.9-2007.6,,  中山大學(xué),生物化學(xué)與分子生物學(xué),,博士

    1998.9-2002.6,,  中山大學(xué),生物化學(xué),,學(xué)士

社會(huì)兼職:

Frontiers in Cardiovascular Medicine雜志副主編

廣東省醫(yī)學(xué)會(huì)心血管分會(huì)基礎(chǔ)研究學(xué)組副組長(zhǎng)

論著:

【代表性論文】(#共同第一作者,,*通訊作者)

Yan, Y.#, Tang, R. #, Li, B. #, Cheng, L.#, Ye, S., Yang, T., Han, Y.C., Liu, C., Dong, Y., Qu, L.H., Lui, K.O., Yang, J.H.* and Huang, Z.P.* The cardiac translational landscape reveals that micropeptides are new players involved in cardiomyocyte hypertrophy. Molecular Therapy. 2021, 29: 2253-2267. (IF: 12.91)

He, X.#, Liu, J.#, Gu, F., Chen, J., Lu, Y.W., Ding, J., Guo, H., Nie, M., Kataoka, M., Lin, Z., Hu, X., Chen, H., Liao, X., Dong, Y., Min, W., Deng, Z.L., Pu, W.T., Huang, Z.P.* and Wang, D.Z.* Cardiac CIP protein regulates dystrophic cardiomyopathy. Molecular Therapy. 2022, 30: 898-914. (IF: 12.91)

He, X.#, Du, T.#, Long, T.#, Liao, X.*, Dong, Y.*, Huang, Z.P.* Signaling cascades in the failing heart and emerging therapeutic strategies. Signal Transduction and Targeted Therapy. 2022, 7:134. (IF: 38.104)

Huang, Z.P.* and Wang, D.Z*. miR-22 in smooth muscle cells, a potential therapy for cardiovascular disease. Circulation. 2018, 137:1842-1845. (IF: 39.918)

Tang, R.#, Long, T.#, Lui, K.O., Chen, Y., and Huang, Z.P.* A Roadmap for Fixing the Heart: RNA Regulatory Networks in Cardiac Disease. Molecular Therapy - Nucleic Acids. 2020, 20:673-686. (IF: 10.183)

Huang, Z.P., Kataoka, M., Chen, J., Wu, G., Ding, J., Nie, M., Lin, Z., Liu, J., Hu, X., Ma, L., Zhou, B., Wakimoto, H., Zeng, C., Kyselovic, J., Deng, Z.L., Seidman, C.E., Seidman, J.G., Pu, W.T. and Wang, D.Z.* Cardiomyocyte-enriched protein CIP protects against pathophysiological stresses and regulates cardiac homeostasis. The Journal of clinical investigation. 2015, 125: 4122-4134. (IF: 19.456)

Huang, Z.P.#, Ding, Y.#*, Chen, J., Wu, G., Kataoka, M., Hu, Y., Yang, J.H., Liu, J., Drakos, S.G., Selzman, C.H., Kyselovic, J., Qu, L.H., dos Remedios C.G., Pu W.T. and Wang D.Z.* Long non-coding RNAs link extracellular matrix gene expression to ischemic cardiomyopathy. Cardiovascular Research. 2016, 112: 543-554.  (IF: 13.081)

Huang, Z.P.#, Chen, J.#, Seok, H.Y., Zhang, Z., Kataoka, M., Hu, X. and Wang, D.Z.* MicroRNA-22 Regulates Cardiac Hypertrophy and Remodeling in Response to Stress. Circulation Research, 2013, 112: 1234-1243. (IF: 23.213)

Huang, Z.P., Seok, H.Y., Zhou, B., Chen, J., Chen, J., Tao, Y., Pu, W.T., and Wang, D.Z.* CIP, a cardiac ISL1-interacting protein, represses cardiomyocyte hypertrophy. Circulation Research, 2012, 110: 818-830. (IF: 23.213)

Huang, Z.P., Chen, J.F., Regan, J.N., Maguire, C.T., Tang, R.H., Dong, X.R., Majesky, M.W., and Wang, D.Z.* Loss of MicroRNAs in Neural Crest Leads to Cardiovascular Syndromes Resembling Human Congenital Heart Defects. Arteriosclerosis, thrombosis, and vascular biology, 2010, 30: 2575-2586. (IF: 10.514)

其他主要工作成績(jī)(比如獲獎(jiǎng)情況):

    獲廣東省杰出青年醫(yī)學(xué)人才、廣東省“珠江人才計(jì)劃”引進(jìn)青年拔尖人才等人才項(xiàng)目/稱號(hào),;曾獲得美國國立衛(wèi)生研究院的Ruth L. Kirschstein國家研究獎(jiǎng),。主持國家自然科學(xué)基金委面上項(xiàng)目、廣東省自然科學(xué)基金杰出青年項(xiàng)目,、廣東省國際科技合作領(lǐng)域項(xiàng)目等